MedTrace Logo

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

NCT06233942 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 308

Last updated 2026-04-15

No results posted yet for this study

Summary

This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

BG-C9074

administered by intravenous infusion

DRUG

Tislelizumab

administered by intravenous infusion

DRUG

Bevacizumab

administered by intravenous infusion

Sponsors & Collaborators

  • BeOne Medicines

    lead INDUSTRY

Principal Investigators

  • Study Director · BeOne Medicines

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-12
Primary Completion
2027-09-28
Completion
2028-05-15
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • China
  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06233942 on ClinicalTrials.gov